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Abstract HIV protein gp120 in combination with T cell antigen
receptor (TCR) triggering induces apoptosis (gp120-apoptosis) in
Th1 cells. Gp120-apoptosis occurs by induction of Fas-L and
subsequent triggering of the Fas apoptotic pathway. Here,
through the use of several compounds inhibiting induction of Fas-
L, we show that, in a Th1 clone, a protein kinase C (PKC)
independent pathway activated by TCR stimulation is distin-
guishible from a PKC dependent pathway activated by either
phorbol 12-myristate 13-acetate (PMA)/ionomycin or asynchro-
nous stimulation of TCR and CD4 as occurs in gp120-apoptosis.
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1. Introduction
It has been suggested that depletion of CD4 T lympho-
cytes during HIV-1 infection results mostly from indirect kill-
ing of uninfected cells [1]. Accordingly, CD4 T cells from
healthy donors undergo apoptosis after HIV-gp120/CD4
cross-linking (CD4XL) followed by CD3/T cell antigen recep-
tor (TCR) activation (gp120-apoptosis) [2^4].
The hypothesis that gp120-apoptosis could be an exacerba-
tion of activation induced cell death (AICD) proposed by
Westendorp et al. [5], has been con¢rmed by us in CD4
Th1 clones [4]. During gp120-apoptosis two phases actually
occur: (i) the induction phase, in which Fas(APO-1/CD95)-L
is upregulated, and (ii) the e¡ector phase, consisting of apop-
totic cell death after Fas/Fas-L interaction [4].
The Fas/Fas-L apoptosis has a role in tissue homeostasis,
embryogenesis, immune development and homeostatic regula-
tion of normal immune responses [6]. Fas/Fas-L is likely in-
volved in transplants rejection and graft versus host disease
(GVHD) [7]. Alterations of the Fas/Fas-L system have been
described in immune disorders such as autoimmune diseases
[8] and AIDS [9]. Upregulation of Fas expression and in-
creased sensitivity to Fas-agonist mediated apoptosis have
been observed in lymphocytes from HIV patients [9]. HIV-
1 infection is, indeed, responsible for Fas-L production by
monocytes [10,11] and soluble Fas-L is higher in serum
from HIV patients than from healthy donors [9]. These
data suggest a role for Fas/Fas-L induced apoptosis in
AIDS disease and are strengthened by in vitro studies showing
that HIV proteins may induce Fas-L expression in uninfected
T cells [4,5,12].
Although the events downstream Fas triggering have been
studied in detail [6,13,14], little is known about the pathway
leading to Fas-L induction. In T lymphocytes Fas-L upregu-
lation occurs in conditions of hyper-activation (such as in
AICD) [15] or following the treatment with phorbol 12-myr-
istate 13-acetate (PMA)/ionomycin (PMA/io) [5,16]. Fas-L
can also be induced by CD4 cross-linking (CD4XL) in
PBMC [17] and in Th1 clones following TCR stimulation [4].
In our system, several compounds are able to prevent
gp120-apoptosis acting either on Fas-L induction or down-
stream Fas/Fas-L interaction [18]. They include two protein
tyrosine kinase (PTK) inhibitors: genistein (with a broad
spectrum of activity) and PNU152518 (likely targeting Met
or Abl [18]), the immunosuppressant cyclosporin A (known
to a¡ect the calmodulin/calcineurin pathway) and the anti-
oxidants reduced glutathione and ascorbic acid. PTK inhibi-
tors a¡ect both phases of gp120-apoptosis, whereas cyclospor-
in A and anti-oxidants impair Fas-L induction and Fas/Fas-L
donwstream events, respectively.
Here we evaluated whether gp120-apoptosis induces Fas-L
expression through a pathway common to that of PMA/io or
that of TCR hyperactivation. Our aim was to inhibit the in-
duction of Fas-L that follows the sequential triggering of CD4
and TCR (as in gp120-apoptosis) but not that induced by
TCR triggering only (as in Ag-induced apoptosis). We fo-
cused on the role of protein kinase C (PKC) that has been
shown necessary for Fas-L induction by PMA/io but not by
TCR hyperactivation (AICD) in CD8 T cells [19]. We tested
whether PKC inhibition could impair gp120-apoptosis by reg-
ulating Fas-L. Moreover, we evaluated which inhibitors of
gp120-apoptosis [18] are able to prevent Fas-L induction by
the PKC dependent PMA/io.
2. Materials and methods
2.1. Cells
Clone 103, a human CD3 CD4 Th1 clone, has been previously
described [3,4].
2.2. Induction of apoptosis
Cells were seeded at 106 cells/ml in 48-well plates in the presence or
absence of 50 Wg/ml precoated (1 h at 37‡C) anti-TCR mAb
(BMA031) [20] for AICD, 1 Wg/ml anti-Fas mAb (CH-11) (MBL,
Nagoya, Japan) for anti-Fas-apoptosis, or 10 ng/ml PMA (Sigma,
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St. Louis, MO, USA) and 500 ng/ml ionomycin (Calbiochem, Nova-
biochem, La Jolla, CA, USA) for PMA/io-apoptosis. Gp120-apopto-
sis was induced by treatment with recombinant HIV-1 gp120 (Intra-
cel, London, UK), anti-gp120 and anti-TCR, as described [4]. Cell
death was evaluated at 4 h by terminal deoxynucleotidyl transfer-
ase-mediated dUTP nick end labelling (TUNEL) [4].
To represent data from several experiments, % apoptotic cells is
expressed as ‘% relative apoptosis’ calculated considering the net value
of apoptotic cells in each experiment as 100%. Net % of apoptosis was
calculated subtracting % apoptosis in the presence of anti-TCR alone
for gp120-apoptosis (12.55 þ 6.55 in 11 independent experiments), or %
apoptosis in medium only for PMA/io-apoptosis (14.75 þ 8.6 in 8 inde-
pendent experiments), AICD (13.67 þ 1.5 in 3 independent experi-
ments) and anti-Fas apoptosis (30 þ 15 in 3 independent experiments).
2.3. Inhibition of apoptosis
For inhibition experiments, cells (107/ml) were pre-treated for
30 min at 37‡C with medium only or with the following agents, at
doses previously determined to be non-cytotoxic (not shown): cyclo-
sporin A (Sandimmun, Sandoz, Basel, Switzerland) (50 Wg/ml), geni-
stein (Calbiochem) (10 WM), PNU152518 (Pharmacia and Upjohn)
(10 WM), L-ascorbic acid (Sigma) (500 WM) or reduced glutathione
(Tationil, Boehringer Mannheim Italia, Milan, Italy) (500 Wg/ml), cal-
phostin C (Sigma) (5 nM), H-7 (Calbiochem) (5 WM). Apoptosis was
then induced following the already described protocols. Inhibitors
were maintained, at the same doses used for pre-treatment, through-
out all passages of apoptosis induction and culture. To test inhibition
with calphostin C, samples were kept exposed to light during all
passages as calphostin C is not active in the dark [21]. Light exposure,
per se, did not a¡ect our results (not shown).
For each experiment, relative % apoptosis in the presence of any
inhibitor was calculated as follows: [(net % apoptosis with inhibitor/
net % apoptosis without inhibitor)U100].
2.4. Assay for functional Fas-L
Functional Fas-L expression was evaluated as previously described,
by analyzing the ability of clone 103 to lyse Fas Jurkat cells in a Fas-
dependent manner [4]. For inhibition experiments, clone 103 cells were
treated with inhibitors (same doses and conditions used for apoptosis
experiments) 30 min at 37‡C prior to and during the incubation for
Fas-L induction.
For each experiment, relative % lysis in the presence of any inhib-
itor was calculated as follows: [(% lysis with inhibitor/% lysis without
inhibitor)U100].
2.5. Immunocytochemical analysis
Cytospins (2U105 cells/each) were prepared 1^4 h after induction of
gp120- or PMA/io-apoptosis, respectively, with or without inhibitors.
The slides were dried and stained within 24 h. Samples were ¢xed with
PFA 4% in PBS, then permeabilized with 0.1% Triton X-100. To
neutralize endogenous peroxidases they were treated for 5 min with
3% H2O2 in Met-OH. After blocking with 5% pooled human AB
heat-inactivated serum, samples were incubated with anti-Fas Ligand
clone 33 (Transduction Laboratories, Lexington, KY, USA) 1 h at
room temperature, then washed and incubated with a biotinylated
anti-mouse secondary antibody (Sigma, St Louis, MO, USA) 30 min
at room temperature. To amplify the staining, the TSA-direct Kit
(NEN Life Science Products, Brussels, Belgium) was employed ac-
cording to the manufacturer’s indications. Brie£y, after blocking, sam-
ples were incubated with streptavidin-conjugated HRP for 30 min,
then washed and incubated with FITC-conjugated Tyramide for
7 min. Cells were then washed and counterstained 10 min with
25 Wg/ml PI (Sigma). Slides were observed under a confocal micros-
cope TCS4D Leica (Leica, Heidelberg, Germany). Negative and pos-
itive controls were cells stained with isotype-matched irrelevant mAb
(Cymbus Bioscience, Southampton, UK) and anti-MHC class I mAb,
respectively (not shown).
2.6. RNA extraction and RT-PCR
Semiquantitative reverse transcription-polymerase chain reaction
analysis was performed according to standard procedures. Brie£y,
total RNA was extracted by the standard guanidium thiocyanate-
CsCl technique. Total RNA obtained from 105 cells was reverse tran-
scribed with oligo-dT as the primer. After S26 normalization (25 PCR
cycles), an aliquot of RT-RNA was ampli¢ed. Fas-L RT-RNA am-
pli¢cation within the linear range was obtained by 35 PCR cycles (i.e.
this cycle number allowed a linear RT-RNA dose response). PCR
products were analyzed by Southern blotting with an internal oligom-
er as probe. The sequences of the S26 primers are: forward 5P-G-
CCTCCAAGATGACAAAG-3P (nucleotides (nt) 15^32) and reverse
5P-CCAGAGAATAGCCTGTCT-3P (nt 395^412); probe GAGCG-
TCTTCGATGCCTATGTGCTTCCCAA (from nt 191 to nt 220)
[22]. PCR conditions: 95‡C, 45 s; 56‡C, 45 s; 72‡C, 45 s. The sequen-
ces of Fas-L primers are: forward 5P-CAAGTCCAACTCAAGGTC-
CAT-3P (nt 641^661) and reverse 5P-AACGTATCTGAGCTCTC-
TCTG-3P (nt 966^986); probe 5P-ACCTATGGAATTGTCCTG-
CTTTCTGGAGTG-3P (nt 681^710) [23]. PCR conditions: 95‡C,
45 s; 55‡C, 45 s; 72‡C, 45 s. The Fas-L expression level, normalized
to S26, was analyzed by a phosphorimager (Molecular Dynamics,
Sunnyvale, CA, USA).
3. Results
3.1. PKC role in Fas-L induction during AICD, gp120- or
PMA/io-apoptosis
To evaluate whether stimulation of gp120-apoptosis may
induce Fas-L through a pathway common to that activated
by either PMA/io or hyperactivation of TCR, we tested the
role of PKC. Fas-L upregulation was evaluated by its ability
to kill, in a Fas-dependent fashion, a sensitive target such as
the Jurkat cell line. Cells of CD4 clone 103 were stimulated
to induce AICD, gp120-apoptosis or were stimulated with
PMA/io in the presence or absence of the speci¢c PKC inhib-
itor calphostin C (Fig. 1A).
PKC inhibition could not prevent Fas-L expression during
AICD, con¢rming the recent evidence obtained by Anel et al.
in CD8 T cells [19]. On the contrary calphostin C inhibits
Fas-L induction by gp120 and PMA/io (Fig. 1A). It is worth
noting that this inhibition takes place only when experiments
are performed in the light (Fig. 1A) but not in the dark (not
shown), a condition in which calphostin C is inactive [21].
These initial data suggest that PMA/io and gp120, but not
AICD, require PKC for Fas-L induction. This hypothesis
was con¢rmed using a di¡erent PKC inhibitor, H-7 (not
shown).
When the e¡ect of calphostin C was tested on apoptosis, we
found that not only gp120-apoptosis and PMA/io-apoptosis
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Fig. 1. PKC role in Fas-L (A) and apoptosis induction (B) by
gp120, PMA/io and AICD. A: Functional Fas-L expression (cyto-
toxicity on Jurkat cells) by clone 103 cells stimulated for AICD
(closed bars), gp120-apoptosis (open bars) or with PMA/io (shaded
bars) were evaluated, in the presence or absence of 5 nM calphostin
C under light exposure, 4 h after induction. (Mean þ S.D. of three
independent experiments.) B: AICD (closed bars), gp120-apoptosis
(open bars), PMA/io-apoptosis (shaded bars) or anti-Fas-apoptosis
(dashed bars) in the presence or absence of 5 nM calphostin C
under light exposure. (Mean þ S.D. from 2 independent experiments
is shown.)
P. Accornero et al./FEBS Letters 436 (1998) 461^465462
but also AICD were inhibited (Fig. 1B). This ¢nding suggests
that, although di¡erentially required for Fas-L induction,
PKC is part of the pathway downstream Fas triggering, lead-
ing to apoptosis. In fact calphostin C blocks apoptosis directly
induced by anti-Fas agonistic mAb (Fig. 1B).
3.2. A common pathway of Fas-L induction by gp120 or
PMA/io stimulation
PKC was required for Fas-L induction during both gp120-
and PMA/io-apoptosis suggesting the activation of a common
pathway. Thus we tested whether other compounds already
found to block gp120-apoptosis [18] may inhibit PMA/io-
apoptosis.
We evaluated induction of apoptosis (Fig. 2A) and func-
tional Fas-L (Fig. 2B) by PMA/io in the presence of the in-
hibitory compounds. PTK inhibitors PNU152518 and genis-
tein, as well as the Ca2-dependent calcineurin inhibitor,
cyclosporin A, were able to inhibit both apoptosis and Fas-
L induction (Fas-L-dependent lytic activity) (Fig. 2). Further-
more, anti-oxidants ascorbic acid (Fig. 2A) and glutathione
(not shown) acting downstream Fas/Fas-L interaction only
inhibited PMA/io induced apoptosis.
These results suggest that PMA/io and gp120 activate a
common signalling pathway inducing Fas-L that involves
calmodulin/calcineurin, one or more PTK as well as PKC.
3.3. Immunocytochemical analysis of Fas-L expression
In Fig. 2B, Fas-L expression was measured indirectly by its
ability to lyse Fas susceptible Jurkat cells. To directly test the
e¡ect of inhibitory compounds on Fas-L expression induced
by gp120 or PMA/io, immunocytochemistry was assessed.
To increase the detection of Fas-L an ampli¢cation kit
(MM) was used on cytospins. Fig. 3 shows microphotographs
from one of three independent experiments in which clone 103
cells were treated for gp120- (left panel) or PMA/io-apoptosis
(right panel) in the presence or absence of the indicated in-
hibitors. Basal expression of Fas-L is shown by cells cultured
with anti-TCR mAb (A), or in medium only (B). Con¢rming
our previous data (here and [18]), Fas-L expression was up-
regulated by both gp120- and PMA/io-treatment (Fig. 3C and
D, respectively). Fas-L upregulation by both treatments was
inhibited by PNU152518 (E and F), genistein (not shown),
calphostin C (G and H) and CsA (K and L). Ascorbic acid
(I and J) and GSH (not shown) had no e¡ect.
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Fig. 2. Activity of inhibitory compounds on apoptosis (A) and func-
tional Fas-L expression (B) induced by PMA/io stimulation. Clone
103 cells were cultured for 4 h with PMA/io in the presence or ab-
sence of the indicated agents. Apoptosis (A) and functional Fas-L
expression (B) were then evaluated by TUNEL and cytotoxic activ-
ity against Fas Jurkat cells, respectively. (Mean þ S.D. of 4 inde-
pendent experiments is shown.)
Fig. 3. Modulation of Fas-L expression by several inhibitors in the
gp120 or PMA/io models. Immunocytochemical analysis of Fas-L
expression in gp120-apoptosis or PMA/io treated cells. The left side
of the panel shows samples 1 h after induction of gp120-apoptosis,
the right side of the panel shows cells cultured for 4 h. with PMA/
io. Basal Fas-L expression is indicated by anti-TCR stimulated cells
(A) and cells cultured in medium only (B). Cells were stimulated for
gp120-apoptosis (C) or PMA/io (D) in medium only, or in the pres-
ence of 10 WM PNU152518 (E^F), 5 nM calphostin C (G^H),
500 Wg/ml ascorbic acid (I^J) or 50 Wg/ml cyclosporin A (K^L).
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This immunocytochemical analysis con¢rms the previous
data indicating the existence of a common pathway for Fas-
L induction during gp120- and PMA/io-apoptosis.
3.4. Fas-L regulation at mRNA level
Functional data and the immunocytochemical staining
showed that some compounds can inhibit Fas-L induction
by gp120 or PMA/io. To test whether such inhibition occurs
at transcriptional level, RT-PCR analysis was performed.
Kinetic experiments showed that Fas-L mRNA could be
detected as early as 30 min after gp120- or PMA/io-stimula-
tion, but not after TCR activation (not shown). Thus the
analysis of Fas-L induction in the presence of the inhibitory
compounds was performed after 30 min of stimulation. Phos-
phorimager analysis of PMA/io and gp120 treated cells is
represented in Fig. 4 (A and B, respectively). CsA,
PNU152518, and calphostin C (used under light) impaired
upregulation of Fas-L mRNA.
Semiquantitative analysis indicates that PMA/io stimulation
induces about three times more Fas-L than gp120-apoptosis
(Fig. 4). This was in agreement with the functional data, in
fact Jurkat cell lysis by clone 103 stimulated with PMA/io or
gp120 was 38 þ 5% and 15 þ 3%, respectively.
4. Discussion
To explain the immunode¢ciency occurring after HIV in-
fection two major mechanisms have been hypothesized: a di-
rect cytopathic e¡ect of the virus on the infected lymphocytes
[24] and the induction of apoptotic death of uninfected CD4
T cells [10,25]. In vitro models and clinical studies suggest that
both mechanisms are likely to be responsible of CD4 T cells
depletion. Indeed some viral proteins can induce cell death of
uninfected lymphocytes either directly [26,27] or in association
with TCR stimulation [5]. In particular, gp120, a protein of
the viral envelope that binds CD4, determines apoptotic cell
death of CD4 lymphocytes when TCR is also triggered
[2,28]. We recently demonstrated that gp120-apoptosis occurs
in Th1 but not in Th2 clones and that it is mediated by
induction of Fas-L and triggering of the Fas apoptotic path-
way [4]. This is likely a sensitization to AICD, in fact gp120-
apoptosis follows standard TCR activation (we use a dose of
anti-TCR mAb that alone induces proliferation and cytokine
production) [4]. In the present paper we compared the path-
way leading to Fas-L expression induced during gp120-apop-
tosis, AICD and PMA/io stimulation.
Anel et al. [19] recently showed that, in CD8 T cells, PKC
is necessary for Fas-L induction by PMA/io but not by hyper-
activation of TCR such as in AICD. We con¢rm these data in
a CD4 Th1 clone and further observe that PKC is necessary
for inducing Fas-L when CD4XL precedes TCR triggering.
Thus it is possible to distinguish a ‘physiologic’ PKC inde-
pendent pathway that is activated by antigenic stimulation of
TCR (as supposed for controlling the expansion of activated
clones in vivo [29]) and a ‘pathologic’ PKC dependent path-
way that is activated when TCR and CD4 are asynchronously
stimulated. This may contrast with the general idea that CD4
is an accessory receptor potentiating the TCR stimulation, an
event that occurs when the two receptors are contemporane-
ously activated [30]. These data are apparently in disagree-
ment with a recent study demonstrating that when CD4XL
precedes TCR activation Fas-L is not induced and tyrosine
phosphorylation is prevented [31]. In fact a di¡erence was
reported between short and long term cultured clones, sug-
gesting that the PKC-dependent Fas-L induction is restricted
to long term stimulated clones, such as our clone 103. We
underline that long term activated CD4 T cell clones can
be considered a valuable model to study T cell depletion in
HIV infection since they allow to reproduce results obtained
by others using bulk cultures [2,32]. These clones could mimic
the in vivo setting where HIV infection determines a strong
and prolonged stimulation of the immune system [33]. It is
likely that the chronically activated T lymphocytes undergo
apoptosis [34].
In our model asynchronous activation of CD4 and TCR
induces Fas-L via PKC. In addition to Fas-L induction,
PKC acts downstream Fas/Fas-L interaction. Whether PKC
participate to Fas-apoptosis has been debated [35^37] but not
directly studied. Our data strongly support a PKC role in
anti-Fas induced apoptosis in CD4 T cell clones; whether
PKC operates toward the activation of caspases [38] or GD3
[14] remains to be studied.
PMA/io stimulation and gp120-apoptosis activate a com-
mon pathway for Fas-L induction. This pathway involves
PKC, one or more PTK and the Ca2-dependent calcineurin.
Evidence from other authors indicates that CsA can prevent
Fas-L mRNA transcription induced by PMA/io stimulation
[19], and that a CsA sensitive transcriptional regulation of
Fas-L induced by either PMA/io or TCR/CD3 activation
may involve NFUB [39], NF-ATp [40] and/or Egr activation
[41].
Our data contribute to the knowledge of events leading to
Fas-L expression in CD4 T lymphocytes. The importance of
understanding this mechanism is based on the possibility to
interfere with the pathologies characterized by altered expres-
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Fig. 4. E¡ect of the inhibitory compounds on Fas-L mRNA induc-
tion. Phosphorimager analysis of PMA/io (B) or gp120 (C) treated
cells 30 min after induction in the presence or absence of the indi-
cated compounds (S26 mRNA was used as a control). One of two
independent experiments is shown.
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sion of Fas-L, including AIDS and several autoimmune dis-
eases (LES, autoimmune diabetes, Ashimoto’s thyroiditis) [8].
Although further studies are necessary to better de¢ne the
pathway regulating Fas-L expression, our data indicate the
possibility of preventing its induction after an asynchronous
triggering of CD4 and TCR (such as in gp120-apoptosis)
without a¡ecting the more physiologic Ag-mediated AICD.
We suggest that, following TCR triggering, activation of
PKC may redirect a positive response (proliferation and cy-
tokine production) to a negative one (cell death). An aspeci¢c
stimulation, like PMA/io, can activate the PKC dependent
pathway in the absence of CD4 and TCR triggering; we do
not know whether PMA/io activates other cytoplasmic com-
ponents, besides PKC, to induce Fas-L.
These ¢ndings suggest the possibility for a new pharmaco-
logical approach for pathologies involving an unregulated ex-
pression of Fas-L such as AIDS. At the moment treatment of
AIDS is directed to control T lymphocyte infection and virus
replication. Encouraging new therapies are waiting for a long
follow-up validation in the light of the high virus variability
and possible existence of silent virus reservoirs in the host.
The possibility of controlling Fas-L expression and thus of
preventing death of uninfected T lymphocytes, may help to
preserve the immune system.
Acknowledgements: We thank Mr Mario Azzini for the ¢gures. This
work was supported by the Italian Ministry of Health (VI, VII, VIII,
IX and X projects on AIDS). A.P. and M.R. are recipients of an
Italian Ministry of Health ISS Fellowship.
References
[1] Pantaleo, G. and Fauci, A.S. (1995) Nat. Med. 1, 118^120.
[2] Banda, N.K., Bernier, J., Kurahara, D.K., Kurrle, R., Haig-
wood, N., Sekaly, R.-P. and Finkel, T.H. (1992) J. Exp. Med.
176, 1099^1106.
[3] Radrizzani, M., Accornero, P., Amidei, A., Aiello, A., Delia, D.,
Kurrle, R. and Colombo, M.P. (1995) Cell. Immunol. 161, 14^21.
[4] Accornero, P., Radrizzani, M., Delia, D., Gerosa, F., Kurrle, R.
and Colombo, M.P. (1997) Blood 89, 558^569.
[5] Westendorp, M.O., Frank, R., Ochsenbauer, C., Stricker, K.,
Dhein, J., Walczak, H., Debatin, K.M. and Krammer, P.H.
(1995) Nature 375, 497^500.
[6] Nagata, S. (1997) Cell 88, 355^365.
[7] Signore, A., Annovazzi, A., Procaccini, E., Beales, P.E., Spnecer,
J., Testi, R. and Ruberti, G. (1997) Diabetologia 40, 1476^1479.
[8] De Maria, R. and Testi, R. (1998) Immunol. Today 19, 121^125.
[9] Sloand, E.M., Young, N.S., Kumar, P., Weichold, F.F., Sato, T.
and Maciejewski, J.P. (1997) Blood 89, 1357^1363.
[10] Mitra, D., Steiner, M., Lynch, D.H., Staiano-Coico, L. and Lau-
rence, J. (1996) Immunology 87, 581^585.
[11] Badley, A.D., McElhinny, J.A., Leibson, P.J., Lynch, D.H., Al-
derson, M.R. and Paya, C.V. (1996) J. Virol. 70, 199^206.
[12] Peter, M.E., Ehret, A., Berndt, C. and Krammer, P.H. (1997) Br.
Med. Bull. 52, 604^616.
[13] Krammer, P.H., Dhein, J., Walczak, H., Behrmann, I., Mriani,
S., Matiba, B., Fath, M., Daniel, P.T., Knipping, E., Westen-
dorp, M.O., Stricker, K., Baºumler, C., Hellbardt, S., Germer,
M., Peter, M.E. and Debatin, K.M. (1994) Immunol. Rev. 142,
175^191.
[14] De Maria, R., Rippo, M.R., Schuchman, E.H. and Testi, R.
(1998) J. Exp. Med. 187, 897^902.
[15] Brunner, T., Mogil, R.J., LaFace, D., Yoo, N.J., Mahboubi, A.,
Echeverry, F., Martin, S.J., Force, W.R., Lynch, D.H., Ware,
C.F. and Green, D.R. (1995) Nature 373, 441^444.
[16] Anel, A., Buferne, M., Boyer, C., Schmitt-Verhulst, A.M. and
Golstein, P. (1994) Eur. J. Immunol. 24, 2469^2476.
[17] Oyaizu (1997) J. Immunol. 158, 2456^2463.
[18] Radrizzani, M., Accornero, P., Delia, D., Kurrle, R. and Clom-
bo, M.P. (1997) FEBS Lett. 411, 87^92.
[19] Anel, A., Simon, A.K., Auphan, N., Buferne, M., Boyer, C.,
Golstein, P. and Schmitt-Verhulst, A.M. (1995) Eur. J. Immunol.
25, 3381^3387.
[20] Borst, J., Van Dongen, J.J.M., De Vires, E., Comans-Bitter,
W.M., Van Tol, M.J.D. and Kurrle, R. (1990) Hum. Immunol.
29, 175.
[21] Bruns, R.F., Miller, F.D., Merriman, R.L., Howbert, J.J., Heath,
W.F., Kobayashi, E., Takahashi, I., Tamaoki, T. and Nakano,
H. (1991) Biochem. Biophys. Res. Commun. 176, 288^293.
[22] Vincent, S., Marty, L. and Fort, P. (1993) Nucleic Acids Res. 21,
1498^1501.
[23] Mita, E., Hayashi, N., Iio, S., Takehara, T., Hijioka, T., Kasa-
hara, A., Fusamoto, H. and Kamada, T. (1994) Biochem. Bio-
phys. Res. Commun. 204, 468^474.
[24] Gandhi, T.R., Chen, B.K., Starus, S.E., Dale, J.K., Lenardo,
M.J. and Baltimore, D. (1998) J. Exp. Med. 187, 1113^1122.
[25] Anderson, R.W., Ascher, M.S. and Sheppard, H.W. (1998)
J. Acquired Immune De¢c. Syndr. Hum. Retrovirol. 17, 245^252.
[26] Fuji, Y. (1996) FEBS Lett. 393, 93^96.
[27] McCloskey, T.W., Ott, M., Tribble, E., Khan, S.A., Teichberg,
S., Paul, M.O., Pahwa, S., Verdin, E. and Chirmule, N. (1997)
J. Immunol. 158, 1014^1019.
[28] Cottrez, F., Manca, F., Dalgleish, A.G., Arenzana-Seisdesdos,
F., Capron, A. and Groux, H. (1997) J. Crit. Illn. 99, 257^266.
[29] Lynch, D.H., Ramsdell, F. and Alderson, M.R. (1995) Immunol.
Today 16, 569^574.
[30] -Zamoyska, R. (1998) Curr. Opin. Immunol. 10, 82^87.
[31] Oberg, H.H., Sanzenbacher, R., Lengl-Janssen, B., Dobmeyer,
T., Flindt, S., Janssen, O. and Kabelitz, D. (1997) J. Immunol.
159, 5742^5749.
[32] Oyaizu, N., McCloskey, W., Coronesi, M., Chirmule, N., Kalya-
naraman, V.S. and Pahwa, S. (1993) Blood 82, 3392^3400.
[33] Gougeon, M.L., Colizzi, V., Dalgleish, A. and Montagnier, L.
(1993) AIDS Res. Hum. Retroviruses 9, 489^493.
[34] Muro-Cacho, C.A., Pantaleo, G. and Fauci, A.S. (1995) J. Im-
munol. 154, 5555^5566.
[35] Egle, A., Villunger, A., Kos, M., Boºck, G., Gruber, J., Auer, B.
and Greil, R. (1996) Eur. J. Immunol. 26, 3119^3126.
[36] Sawai, H., Okazaki, T., Takeda, Y., Tashima, M., Sawada, H.,
Okuma, M., Kishi, S., Umehara, H. and Domae, N. (1997)
J. Biol. Chem. 272, 2452^2458.
[37] Suzuki, A., Goto, Y. and Iguchi, T. (1997) Carcinogenesis 18,
883^887.
[38] Cohen, G.M. (1997) Biochem. J. 326, 1^16.
[39] Matsui, K., Omura, S., Cui, H., Schauer, S.L., Sonenshein, G.E.
and Ju, S.T. (1997) Eur. J. Immunol. 27, 2269^2278.
[40] Latinis, K.M., Carr, L.L., Peterson, E.J., Norian, L.A., Eliason,
S.L. and Koretzky, G.A. (1997) J. Immunol. 158, 4602^4611.
[41] Mittelstadt, P.R. and Ashwell, J.D. (1998) Mol. Cell. Biol. 18,
3744^3751.
FEBS 20887 8-10-98 Cyaan Magenta Geel Zwart
P. Accornero et al./FEBS Letters 436 (1998) 461^465 465
